- Home
- AQST
as 05-09-2025 4:00pm EST
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as Aquestive Therapeutics Inc. AQST prepares to release earnings report on 12 May 2025.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 254.1M | IPO Year: | 2018 |
| Target Price: | $11.40 | AVG Volume (30 days): | 939.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.20 - $5.80 | Next Earning Date: | 05-12-2025 |
| Revenue: | $57,561,000 | Revenue Growth: | 13.79% |
| Revenue Growth (this year): | -12.11% | Revenue Growth (next year): | 39.51% |
Latest Aquestive Therapeutics Inc. News
AQST Breaking Stock News: Dive into AQST Ticker-Specific Updates for Smart Investing
GuruFocus.com
11 hours ago
Aquestive Therapeutics Inc (AQST) Q1 2025: Everything You Need To Know Ahead Of Earnings
GlobeNewswire
5 days ago
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
GlobeNewswire
9 days ago
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
Zacks
25 days ago
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?
GlobeNewswire
a month ago
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
GlobeNewswire
a month ago
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
Simply Wall St.
2 months ago
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts
GuruFocus.com
2 months ago
Aquestive Therapeutics Inc (AQST) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
Compare AQST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AQST Aquestive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.